These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1077 related items for PubMed ID: 29252091

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F.
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
    Goto S, Gomi F, Ueno C, Nishida K.
    Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
    [Abstract] [Full Text] [Related]

  • 26. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Gutiérrez-Hernández JC, Martínez-Camarillo JC, Sadda SR.
    Retin Cases Brief Rep; 2015 Nov; 9(2):109-13. PubMed ID: 25383847
    [Abstract] [Full Text] [Related]

  • 27. One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.
    Ohkuma Y, Hayashi T, Sakai T, Watanabe A, Tsuneoka H.
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1909-17. PubMed ID: 23456099
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy.
    Cidad P, González E, Asencio M, García J.
    Korean J Ophthalmol; 2015 Oct; 29(5):331-5. PubMed ID: 26457039
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
    Smretschnig E, Ansari-Shahrezaei S, Moussa S, Glittenberg C, Krebs I, Binder S.
    Retina; 2012 Oct; 32(10):2014-9. PubMed ID: 22466482
    [Abstract] [Full Text] [Related]

  • 35. Assessment of the efficacy of photodynamic therapy in patients with chronic central serous chorioretinopathy.
    Manethová K, Ernest J, Hrevuš M, Jirásková N.
    Cesk Slov Oftalmol; 2020 Oct; 75(6):298-308. PubMed ID: 32911945
    [Abstract] [Full Text] [Related]

  • 36. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy.
    Munk MR, Shah R, Pappas F, Baddar D, Wong B, Jampol LM, Fawzi AA.
    Curr Eye Res; 2016 Oct; 41(1):97-106. PubMed ID: 25612245
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
    Altinel MG, Kanra AY, Totuk OMG, Ardagil A, Kabadayi K.
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Leys E, Tuttle S, Rasquin F, Neu F, Postelmans L.
    J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.